The article presents the results of an observational study to evaluate the effectiveness of COVID‑19 therapy.The aim of the study. To evaluate the effectiveness of etiotropic therapy in outpatient patients with COVID‑19.Materials and methods. The study included 244 patients with COVID‑19. According to etiotropic starting therapy from the first week of the disease, patients were divided into 3 groups: those who received favipiravir, umifenovir and those who did not receive antiviral agents.Results. The median time and interquartile interval before virus elimination while taking favipiravir was 3 (3.0; 5.0) days, among those taking umifenovir – 5 (3.0; 7.0) days, without antiviral therapy – 8 (7.0; 10.0) days. More often, by day 7 and 14, normalization of body temperature occurred with favipiravir therapy. Among the patients who did not receive antiviral therapy in the first 10 days of the disease, in most (82 %) cases, a deterioration in the condition was registered with hospitalization and correction of the therapy regimen.Conclusions. Taking favipiravir or umifenovir promotes earlier elimination of the virus, faster normalization of body temperature and a favorable outcome of the disease in outpatient patients. Favipiravir leads somewhat faster to the elimination of the virus, a somewhat more frequent improvement in the condition with normalization of body temperature on the 7th day from the start of therapy. However, when using umifenovir, there is less frequency of side effects.
The article presents clinical examples of treatment of patients with COVID-19 diagnosed during the period of active spread of the ‘omicron’ strain. The results of symptomatic therapy and the need for the appointment of etiotropic drugs, including in the late stages of the disease, are considered, which raises the greatest number of questions in clinical practice. In the presented examples, patients received medicines approved by the current temporary guidelines for the diagnosis, treatment and prevention of COVID-19 of the Ministry of Health of the Russian Federation. The analysis of the course of the disease confirms the continuing need for the appointment of etiotropic therapy in the conditions of the spread of the ‘omicron’ variant, including in the second week of the disease. Umifenovir therapy as part of a comprehensive treatment regimen suspends the progression of COVID-19 and leads to relief of symptoms. Symptomatic treatment in the conditions of the spread of a new variant of the coronavirus omicron cannot replace etiotropic and pathogenetic therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.